Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9524)	4/4/1999 8:48:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Bluegreen, the use of clone animal to produce peptides and hormones is not so easy, many more years of research needed. They are some examples like to produce via breast milk, or via plasma. I do not think of it as inherently cheaper. Purity of final molecule is a problem to solve. I do not know of any company with advance antimicrobial peptides, Magainin, The Frog Company, comes to mind. Magainin went the topical treatment way due to problems of rejection and allergies of a foreign protein. Xoma will have Bpi production capabilities ready via the recombinant technique a well try proven method. Maybe Enmd should benefit from something like the clone animal production, they have problem with BMY regarding their yeast recombinant technique. But theirs are not antimicrobial products. Regarding the 2nd topic, physicians who will want the patients in the bpi trial and accept then with Glasgow scores below 8, I do not think this will happen frequently, and they do not know which particular patient will get the drug or placebo.